# Changrun Capital

> Changrun Capital is a VC fund in Shenzhen backing Software and Manufacturing. See 7 investments, check sizes, portfolio and contact details. Updated Sep 2026.

- Type: VC Fund
- Location: Shenzhen, China
- Total investments: 7
- Last investment: Jun 2021
- Lead investor: 43%
- Last updated: Sep 2026
- Website: http://www.crpe.com.cn/

Changrun Capital is an equity and securities investment and investment consulting firm.

## Contacts

5 contacts available for Changrun Capital. Shizune tracks 1 team members at Changrun Capital. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/changrun-capital?utm_source=investor_profile

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Software | 2 | 29% |
| Manufacturing | 2 | 29% |
| Information Technology | 2 | 29% |
| Mobile | 1 | 14% |
| Battery | 1 | 14% |

20 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series A | 2 | 29% |
| Series B | 2 | 29% |
| Series C | 1 | 14% |
| Post-IPO Equity | 1 | 14% |
| Venture - Series Unknown | 1 | 14% |

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| Wei Wang | Founder and Chairman | 0 | — |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Yunmai | Yunmai is way more than a standard weight scale. Using fitness data technology, lightning fast Bluetooth connectivity, and Body Index analysis capabilities, our body composition scales and mobile app offer actionable insight into your overall health by providing detailed measurements of 10 key body composition measurements.You can easily syncYunmai with a variety of other wellness apps, tools, and technologies such as Apple Health, FitBit, Google Fit, etc. With more data seamlessly streamlined at your fingertips, you can get a better grip on your health. | $31M | Series C | Jun 28, 2021 |  |
| HappyCast | HappyCast develops multi-screen interactive software. Its product can connect smart phone with TV set or projector to display mobile games, live video streaming, video calls and other mobile contents on larger screen. |  | Series A | Sep 23, 2019 |  |
| Knowledge Vision | Knowledge Vision is an innovative R&D company that specializes in pathological artificial intelligence-assisted analysis and is committed to using artificial intelligence to assist doctors in accurate companion diagnostics. The founder team of Knowledge Vision has more than seven years of experience in innovative medical device developmentrelated to machine learning, familiar with the classification criteria for medical devices, clinical trial specifications, production quality system management, registration processes and fee-related regulations. The company develops a cloud-free platform for research and development of codeless AI applications - AI VIEWER, which utilizes data encryption and authorization mechanisms to ensure user data security and facilitate multi-party cooperation and data sharing. By collecting pathological AI to analyze the commonality of clinical application requirements, standardize and modularize the technologies involved in the research and development of pathological AI, and realize the whole process of data management, image annotation, algorithm development and application release required for pathological AI application research and development. And qualitative, localized, quantitative and visualized, digital analysis of histological pathology. AI VIEWER can be widely used in the pathological analysis of new drug research and development, and is committed to improving the efficiency and quality of drug development CRO. In the process of new drug research and development, AI VIEWER can realize the auxiliary quantitative analysis of digital pathological images, provide visual prediction data for drug researchers, realize traceability, quality assurance and quality control of pathological analysis process, reduce drug development cost and clinical trial risk. To enhance the market competitiveness of drugs. At the same time, the pathological diagnosis results based on quantitative analysis provide intelligent drug-assisted decision-making for new drug researchers, determine the correlation between pathological data characteristics and prognosis, improve the efficiency and progress of quantitative analysis of pathological sections, and ensure the consistency of histopathological analysis. It can be used for screening of subjects and for the determination of concomitant diagnostic cutoff values. | $1.4M | Series A | Jun 14, 2019 |  |
| Shuwei | Shuwei is an indoor positioning services provider for mobile Internet platforms and smartphone manufacturers.Its technology is applied to shopping malls, train stations, office buildings, and restaurants. Shuwei also launched an open precision marketing platform that offers relevant content related to the vehicle, as well as information aboutsimilar cars.The Shenzhen, Guangdon-based company was established in 2014. |  | Series B | Jul 24, 2018 |  |
| Sinolion | Sinolion provides logistics solutions for subsequent packaging production lines, such as product testing, sorting and conveying, packing boxes, and winding. They serve food and beverages, glass fiber and chemical fiber, chemical coatings, and building materials. The company will continue to be business-driven and driven by technology, steadilypromoting the automation and intelligent development of domestic automated warehousing and logistics. | $7.6M | Post-IPO Equity | Oct 11, 2017 |  |
| HongTu Separator | HongTu Separator manufactures battery separators for specialty applications. The company develops lithium-ion battery separators and common zinc-manganese battery separators with chemical and thermal stability and uniform microporous structure that help automobiles and other industries improve the performance of their electrical equipment.Thecompany was founded in 2005 and is headquartered in Liaoyuan, Jilin. |  | Venture - Series Unknown | Jun 01, 2017 |  |
| Hanshow Technology | Hanshow Technology Co. Ltd offers connected commerce solutions based on its electronic gondola label (EEG) technology . With an experienced research and development team of 140 employees, the company has installed the most comprehensive EEG systems in the world, covering the entire supply chain. |  | Series B | Mar 01, 2017 |  |

7 of 7 investments shown.

## Co-investors
- [Bright Venture Capital](https://shizune.co/investors/profile/bright-venture-capital) — VC Fund, 1 deal together
- [CAS Investment Management](https://shizune.co/investors/profile/cas-investment-management) — VC Fund, 1 deal together
- [Charisma Partners](https://shizune.co/investors/profile/charisma-partners) — VC Fund, 1 deal together
- [Future Capital Discovery Fund](https://shizune.co/investors/profile/futurecap-e45d) — VC Fund, 1 deal together
- Guangdong Guoke — VC Fund, 1 deal together
- Guangzhou Lifeng — VC Fund, 1 deal together

## Similar investors

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [FJ Labs](https://shizune.co/investors/profile/fj-labs) — VC Fund

## FAQ

### What does Changrun Capital invest in?

Changrun Capital invests primarily in Software, Manufacturing and Information Technology startups, most often at Series A and Series B stage. Most of the 7 investments tracked by Shizune back companies in China. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### How do I contact Changrun Capital?

Public channels for Changrun Capital include the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at Changrun Capital?

The team at Changrun Capital includes Wei Wang (Founder and Chairman). The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Sep 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co